Access cutting-edge pulmonary fibrosis treatment through this clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.
Access pulmonary fibrosis specialists in Los Angeles at no cost
This study follows strict safety protocols and ethical guidelines
All study-related pulmonary fibrosis treatment provided free
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks. Cohort 1 has com
Sponsor: Genentech, Inc.
Check if you qualify for this pulmonary fibrosis clinical trial in Los Angeles, CA
If you're searching for pulmonary fibrosis treatment options in Los Angeles, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Los Angeles research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pulmonary fibrosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.